Everyday movement and subjective energy (MASE Project)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MASE project uses wrist-worn accelerometers and electronic momentary diaries to link non-exercise activity (NEA) with real-time reports of subjective energy in daily life. Researchers will identify each person's activity–energy association (ASEA) and combine those data with neural markers to guide personalized behavioral activation that targets incidental movement. The intervention focuses on small, rewarding everyday actions (not structured exercise) to increase NEA and subjective energy, with outcomes including changes in depressive symptoms and relapse risk. Control and comparison groups, including remitted patients and healthy volunteers, are used to differentiate disorder-specific patterns.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Sufficient knowledge of the German language
* Written informed consent.
* Score \> 15 on the Montgomery Asberg Depression rating scale (MADRS) for MDD group.
* Remission within the past year and exhibit a MADRS score \< 10 for at least one month for rMDD group

Exclusion Criteria:

* Pregnancy at baseline
* Claustrophobia
* Pacemaker
* Artificial heart valves
* Active implants
* Other psychiatric disorders
* Acute suicidality, change of medication / psychotherapy during the intervention (not dosage but substance).
* For healthy participants: history of any mental health condition or first-degree relative with affective / psychotic disorder

Where it's running

• University of Bern
  Bern, Switzerland Recruiting

Study contacts

• Study coordinator: Claudio R. Nigg, Prof
• Email: claudio.nigg@unibe.ch
• Phone: 0041316844188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brenipatide added to standard care for adults with major depressive disorder

  This study tests whether brenipatide, given alongside standard care, can help delay the return of depressive symptoms in adults with major depressive disorder.

  Recruiting at 47 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 169 other locations · NCT07775300

• Student Precarity and Psychiatry: How Financial Struggles Relate to Depression and Loneliness

  This observational study looks at whether financial hardship and social isolation are linked to depression, suicidal thoughts, and loneliness among French university students.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, IDF · NCT07618208

• Seltorexant (JNJ-42847922) as monotherapy for adults and older adults with major depressive disorder

  This trial will test whether seltorexant works better than a placebo to reduce depressive symptoms in adults and elderly people with major depressive disorder.

  Recruiting at 53 sites Phase 3 Janssen Research & Development, LLC · Bryant, Arkansas and 52 other locations · NCT07573176

• MOCHA: Inpatient Mental Health Care for High-Risk Pregnancy

  This study tests a collaborative mental health program for pregnant or recently postpartum patients hospitalized for medical problems to see if it can be delivered feasibly and acceptably.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07540585

• Brenipatide added to standard antidepressant treatment for adults with major depression

  This trial will see if adding brenipatide to your current antidepressant treatment can delay the return of major depressive symptoms in adults with major depressive disorder.

  Recruiting at 170 sites Phase 3 Eli Lilly and Company · Moorpark, California and 179 other locations · NCT07412756

• Esketamine plus standard care for adolescents with major depressive disorder and acute suicidal thoughts or behavior

  This will test whether adding intranasal esketamine to usual care helps hospitalized adolescents with major depressive disorder and acute suicidal thoughts or behavior feel better faster than a psychoactive placebo plus usual care.

  Recruiting at 49 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 48 other locations · NCT07227454

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.